Startups target the biology behind age-related infertility

Two European startups are developing treatments to improve the viability of human eggs, aiming to help women trying to conceive in their mid-30s and 40s. They build on research showing why older eggs more often carry abnormal chromosome numbers. By targeting the molecules behind faulty eggs, the firms hope to improve standard IVF, long the only option.